A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

News

News

All the latest news about the Access to Medicine Foundation, our research programmes and engagement activities. 

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

10 Jun 2021

Biotech’s antibiotic warriors need new reward system in superbug fight

Today, a new report by the Foundation examines how small drugmakers, which are pivotal in antibiotic development, are navigating the to...

25 Mar 2021

Handful of new children’s meds on the horizon. But will they be accessible to children in LMICs?

New analysis: Just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in paediatric treatment options.

22 Mar 2021

Foundation welcomes new tool to tackle AMR by enhancing stewardship and access plans

A working group of experts, led by Wellcome Trust, have developed the first ever comprehensive Stewardship and Access Plan (SAP) Development Guide. Pu...

23 Feb 2021

Investors issue urgent call for “fair and equitable” global response to COVID-19

Today, almost 150 institutional investors have issued a joint call for a fair and equitable global response to the pandemic, including through fully f...

25 Jan 2021

Now online: 2021 Access to Medicine Index

Pharma companies move to systematically make new medicines rapidly accessible to the poor. The 2021 Access to Medicine Index identifies eight pha...

24 Nov 2020

The materiality of superbugs: risks and opportunities for pharma investors from antimicrobial resistance

Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimic...

23 Nov 2020

First investor partners named in joint initiative against 'super-sized' AMR threat

As World Antimicrobial Awareness Week begins, 12 global investors and financial institutions have announced they are joining the Investor Action on AM...

20 Nov 2020

Sharing surveillance data: the value of collaboration in curbing the next pandemic

Monitoring the spread of infectious diseases through surveillance programmes is fundamental to maintaining good public health and a key component of s...

20 Oct 2020

Bridging the gap in access to oxygen: Foundation coordinates on key actions for industry

Oxygen is critical in the treatment of pneumonia, which claims the lives of more than 672,000 children under 5 every year. Further, one in five COVID-...

08 Oct 2020

Early look: 5 key lines of investigation for the 2021 Index

Work on the next Access to Medicine Index is well underway. The Index research team is compiling analytical insights for the 20 company report cards,...

06 Oct 2020

2021 Benchmark framework to track pharma's progress against superbugs

The rise of treatment-resistant bacterial and fungal diseases poses a direct threat both to modern medicine and our way of living. The Antimicrobial R...

02 Oct 2020

Which information matters most? Transparency by Pharma that builds access to medicine plus trust and engagement

The world depends on the pharmaceutical industry for life-saving medicines and vaccines yet trust in the industry is low. Pharmaceutical companies hav...

17 Jul 2020

Momentum against AMR, as metrics for next Benchmark take shape

A core group of pharmaceutical companies is making progress against antimicrobial resistance (AMR), as reported in the 2020 Antimicrobial Resista...

16 Jul 2020

Tunnel vision or global outlook? Global pharma's dependency on the US

COVID-19 is a litmus test of whether health systems can pool assets and expertise and fairly distribute resources so that patients worldwide can benef...

10 Jul 2020

Will COVID-19 harm or help pharma's access to medicine efforts, asks 2021 Access to Medicine Index

The next Access to Medicine Index will be published in January 2021 – one year after China imposed the first lockdown to control COVID-19.  The...

09 Jun 2020

Progress against HIV, malaria and TB is under threat, putting children at risk. Here’s what is needed.

COVID-19 and drug resistance are threatening to derail the progress made against the HIV, malaria and TB epidemics. With the last mile in sight, great...

Back to top |